Navigation Links
ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
Date:11/6/2007

placebo. This treatment effect was not observed in the population of beta-1 Gly389 or the alpha-2c deletion carriers, indicating a pharmacogenetic interaction. As for AF prevention and CHF endpoints, patients with the favorable diplotype had treatment effects that were enhanced (reduction by 64% (p =0.001) in VT/VF occurrence by bucindolol as compared to placebo) over those for each individual favorable monotype.

About Bucindolol

Bucindolol is a next-generation beta-blocker and vasodilator for heart failure and other indications, which promises to be the first genetically-targeted cardiovascular drug. Extensive Phase 3 data show that bucindolol is likely to be an effective and well-tolerated therapy for many heart failure patients that can be targeted to those patients most likely to respond favorably, thereby overcoming a major problem with current treatment approaches. ARCA's founding scientists have confirmed genetic polymorphisms that interact with bucindolol's unique pharmacology to modify patient response.

A large substudy from a Phase 3 trial published in the July 25, 2006 edition of the Proceedings of the National Academy of Sciences shows that a common genetic variation in the beta-1 adrenergic receptor may help doctors identify heart failure patients who may benefit most from bucindolol. Data presented at the 2005 American Heart Association Meeting from the same DNA substudy demonstrates further enhancement of bucindolol's efficacy by targeting both the beta-1 variant and a variant of the alpha-2c-adrenergic receptor. A patient's response to bucindolol appears to be affected by genetic variations in two cardiovascular receptors.

ARCA is planning to submit a New Drug Application to the FDA for bucindolol in order to gain approval of the drug with a genetic test to assist physicians in determining whether bucindolol is an appropriate therapy for their heart failure patients. The Company has exclusive, worldwide rights to bucindolol.<
'/>"/>

SOURCE ARCA Discovery, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
2. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
3. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
4. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 2014 /CNW Telbec/ - Ergoresearch Ltd ("Ergoresearch" ... for accelerated growth in terms of sales and profitability. ... $17,862,341. Net income amounted to $1,230,153. The EBITDA reached ... time in the Company,s history. With the ... forces of its subsidiaries, merging in September 2014 Clinique ...
(Date:10/31/2014)... 2014 Research ... of the  "Process Validation in the US and ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,Key topics to ... Approach to Process Validation for Pharmaceutical and Biopharmaceutical ... FDA Process Validation Guidance EU Process ...
(Date:10/31/2014)... 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... , Isis Pharmaceuticals, Third Quarter 2014 Financial Results and ... 11:30 a.m. ET / 8:30 a.m. PTWhere: , ... Simply log onto our website listed above. If you ... replay of the webcast will be available for a ...
Breaking Medicine Technology:Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 2Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 3Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 4Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 5Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 3
... Jan. 19, 2012 /PRNewswire/ --  Terumo Cardiovascular Systems announced ... with LAAx, Inc. to distribute the TigerPaw® System II, ... The TigerPaw System II is indicated ... visualization, in conjunction with other open cardiac procedures.  It ...
... SAN DIEGO, Jan. 19, 2012  Neurocrine Biosciences, Inc. (Nasdaq: ... an underwritten public offering of 9,500,000 shares of its ... $8.10 per share. The gross proceeds to Neurocrine from ... other offering expenses payable by Neurocrine, are expected to ...
Cached Medicine Technology:Terumo Cardiovascular Systems Becomes Exclusive U.S. Distributor for TigerPaw® System II, Left Atrial Appendage Closure Device 2Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock 2Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock 3
(Date:10/31/2014)... 31, 2014 (HealthDay News) -- Sleep apnea may make it ... you parked your car or left your house keys, a ... sleep apnea showed that this ability -- called spatial memory ... (REM) sleep, even when other stages of sleep weren,t affected. ... dreams typically occur. "We,ve shown for the first time ...
(Date:10/31/2014)... say that either they or a family member have ... latest issue of The Gerontological Society of America,s ... which goes on to show that Americans strongly support ... end-of-life health care wishes. , This PP&AR , ... features 12 articles that present new ways of understanding ...
(Date:10/31/2014)... New York (PRWEB) October 31, 2014 ... Mineola Eye in Garden City, Long Island and the ... to their medical staff, according to North Shore Eye ... is the Emeritus Acting Chairman of the Department of ... and successful practice in Garden City for more than ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 FindSurrogateMother.com ... most remarkable gifts of life — building a family ... extraordinary surrogate mothers and donors with hopeful intended parents ... unforeseen circumstances. , It’s a collective aptitude of surrogate ... surrogacy lawyers, and fertility clinics that help provide these ...
(Date:10/31/2014)... 31, 2014 BCC Research ( http://www.bccresearch.com ) ... QUALITY MARKET , the U.S. indoor air quality (IAQ) market ... a compound annual growth rate (CAGR) of 7% over the ... grow at a CAGR of 7.4%. , Since 2012, ... mold, the outbreak of infectious diseases such as bird flu ...
Breaking Medicine News(10 mins):Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Advance directives can benefit patients, families, and health care system 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 3Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 3Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 2Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 3
... A study was conducted by Nathan Thielman, M.D, Duke University ... effective in preventing HIV infections than those which charge a ... testing center and is therefore a very efficient method. ... free testing was conducted by The Duke researchers. Before that ...
... Plans have been announced by the Indian Government to ... which will highlight the achievements of Indian Scientists, //in ... science. The name of the new initiative of the ... for producing a one-hour film and 15 two-minute shorts ...
... most common cancer next to breast cancer in women and ... of cervical cancer would help in early treatment //and help ... cytologic screening test known as Pap smear test is used ... state and could detect early diagnosis. Women above the age ...
... have committed suicide five months ago using a lethal dose of ... degenerative disease// which made her life very traumatic and she had ... to escape from her traumatic pain so she went to Dignitas ... Irwin and Jessica Reid. ,Mrs. Jessica Reid who accompanied ...
... Bio-functional garments like stockings with aloe vera, T-shirts with ... been developed as the textile industry takes its cue ... garments an additional function in addition to keeping the ... their promises is a contentious matter. Experts also fear ...
... bond exists among siblings, even though they compete with each ... parents. The relationship which exists between siblings is very // ... do not welcome the birth of a new baby in ... among siblings. Their relationship has become more like partnerships, partly ...
Cached Medicine News:Health News:Free HIV Tests Brings Crowd to the Testing Centers 2Health News:Scented Garments Hit The Market 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: